FDA
-
-
-
-
-
-
-
HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results
-
-
-
-
-
-
-
HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors
-
-
-
-
-
-
-
HCW Biologics (HCWB) Granted FDA Clearance to Evaluate One of the Company’s Lead Product Candidates
-
-
-
-
-
-
-
HCW Biologics Reports Second Quarter 2022 Financial Results And Recent Business Highlights
-
-
-
-
-
-
-
HCW Biologics to Showcase Two Novel Groups of Fusion Molecules Created with Proprietary and Versatile TOBI™ Platform At the 105th Annual Meeting of the American Association of Immunologists
-
-
-
-
-
-
-
HCW Biologics (HCWB) Announces Masonic Cancer Center at University of Minnesota Receives FDA Clearance to Proceed with Phase 1 Clinical Trial in Solid Tumors for HCW9218
-
-
-
-
-
-
-
HCW Biologics’ Founder and CEO Dr. Hing C. Wong Participating in Cambridge Healthtech Institute’s Annual PepTalk Conference 2022
-
322,748 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

